These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35085385)

  • 41. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
    Montesinos I; Dahma H; Wolff F; Dauby N; Delaunoy S; Wuyts M; Detemmerman C; Duterme C; Vandenberg O; Martin C; Hallin M
    J Clin Virol; 2021 Nov; 144():104988. PubMed ID: 34607239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
    Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
    J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
    Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
    PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.
    Ye X; Angelo LS; Nicholson EG; Iwuchukwu OP; Cabral de Rezende W; Rajan A; Aideyan LO; McBride TJ; Bond N; Santarcangelo P; Rayford YJ; Ferlic-Stark L; Fragoso S; Momin Z; Liu H; Truong K; Lopez B; Conner ME; Rice AP; Kimata JT; Avadhanula V; Piedra PA
    Front Immunol; 2021; 12():693462. PubMed ID: 34691016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories.
    Fischer B; Lichtenberg C; Müller L; Timm J; Fischer J; Knabbe C
    J Clin Virol; 2021 Nov; 144():104984. PubMed ID: 34563863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Ferrer J; Forqué L; Costa R; de la Asunción CS; Huntley D; Gozalbo-Rovira R; Buesa J; Giménez E; Rodríguez-Díaz J; Geller R; Navarro D
    J Med Virol; 2021 Apr; 93(4):2301-2306. PubMed ID: 33236799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies.
    Takahashi M; Ai T; Sinozuka K; Baba Y; Igawa G; Nojiri S; Yamamoto T; Yuri M; Takei S; Saito K; Horiuchi Y; Kanno T; Tobiume M; Khasawneh A; Paran FJ; Hiki M; Wakita M; Miida T; Suzuki T; Okuzawa A; Takahashi K; Naito T; Tabe Y
    Sci Rep; 2022 Sep; 12(1):14909. PubMed ID: 36050347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms.
    Turbett SE; Anahtar M; Dighe AS; Garcia Beltran W; Miller T; Scott H; Durbin SM; Bharadwaj M; Thomas J; Gogakos TS; Astudillo M; Lennerz J; Rosenberg ES; Branda JA
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33020186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody responses to SARS-CoV-2 nucleocapsid and spike proteins in hospitalized patients with COVID-19: A multicenter, retrospective, cross-sectional study in Japan.
    Hibino M; Watanabe S; Tobe S; Maeda K; Horiuchi S; Nishiguchi S; Iwase A; Uryu K; Kobayashi S; Kondo T
    Respir Investig; 2022 Mar; 60(2):256-263. PubMed ID: 34924308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
    Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ
    Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
    Lafon E; Jäger M; Bauer A; Reindl M; Bellmann-Weiler R; Wilflingseder D; Lass-Flörl C; Posch W
    J Allergy Clin Immunol; 2022 Apr; 149(4):1242-1252.e12. PubMed ID: 35093484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods.
    Emmerich P; von Possel R; Hemmer CJ; Fritzsche C; Geerdes-Fenge H; Menge B; Messing C; Borchardt-Lohölter V; Deschermeier C; Steinhagen K
    J Med Virol; 2021 Oct; 93(10):5816-5824. PubMed ID: 34061367
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of virus-specific B-cell epitopes by convalescent plasma from COVID-19 patients.
    Wang L; Zhao J; Schank M; Khanal S; Dang X; Cao D; Nguyen LNT; Zhang Y; Wu XY; Adkins JL; Brueggeman J; Zhang J; Ning S; El Gazzar M; Moorman JP; Yao ZQ
    Mol Immunol; 2022 Dec; 152():215-223. PubMed ID: 36379129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.
    Mariën J; Ceulemans A; Michiels J; Heyndrickx L; Kerkhof K; Foque N; Widdowson MA; Mortgat L; Duysburgh E; Desombere I; Jansens H; Van Esbroeck M; Ariën KK
    J Virol Methods; 2021 Feb; 288():114025. PubMed ID: 33227340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies.
    Cook N; Xu L; Hegazy S; Wheeler BJ; Anderson AR; Critelli N; Yost M; McElroy AK; Shurin MR; Wheeler SE
    Clin Biochem; 2021 Nov; 97():54-61. PubMed ID: 34453893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
    Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
    J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.